A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma

TRC105 is a chimeric monoclonal antibody that targets CD105 (endoglin). Heavily pretreated patients with metastatic urothelial carcinoma received TRC105 at 15 mg/m(2) every 2 weeks on a 28-day cycle. Treatment was not associated with significant toxicities, but did not improve 6-month progression-fr...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Clin Genitourin Cancer
Κύριοι συγγραφείς: Apolo, Andrea B., Karzai, Fatima H., Trepel, Jane B., Alarcon, Sylvia, Lee, Sunmin, Lee, Min-Jung, Tomita, Yusuke, Cao, Liang, Yu, Yunkai, Merino, Maria J., Madan, Ravi A., Parnes, Howard L., Steinberg, Seth M., Rodriguez, Beatriz Walter, Seon, Ben K., Gulley, James L., Arlen, Philip M., Dawson, Nancy A., Figg, William D., Dahut, William L.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: 2016
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6583922/
https://ncbi.nlm.nih.gov/pubmed/27328856
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2016.05.010
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια